<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01211197</url>
  </required_header>
  <id_info>
    <org_study_id>1276.5</org_study_id>
    <secondary_id>2010-018589-22</secondary_id>
    <nct_id>NCT01211197</nct_id>
  </id_info>
  <brief_title>Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability</brief_title>
  <official_title>Relative Bioavailability of a 12.5 mg BI 10773 / 1000 mg Metformin Fixed Dose Combination Tablet Compared With Its Monocomponents and Administered With and Without Food (an Open-label, Randomised, Single-dose, Three-way Crossover, Phase I Trial in Healthy Volunteers)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the current study is to determine the relative bioavailability of a BI 10773
      / metformin fixed dose combination tablet compared to single tablets of BI 10773 and
      metformin when administered together and to assess the effect of food on the bioavailability
      the fixed dose combination tablet
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Empa: Area Under the Curve 0 to Infinity (AUC0-∞)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity.
Note the standard deviation is actually the coefficient of variation (CV).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Empa: Maximum Measured Concentration (Cmax)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Maximum measured concentration of empagliflozin (empa) in plasma.
Note the standard deviation is actually the CV.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metformin: Area Under the Curve 0 to Infinity (AUC0-∞)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Area under the concentration-time curve of metformin in plasma over the time interval from 0 extrapolated to infinity.
Note the standard deviation is actually the CV.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metformin: Maximum Measured Concentration (Cmax)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Maximum measured concentration of metformin in plasma.
Note the standard deviation is actually the CV.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Empa: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the time of the last quantifiable data point.
Note the standard deviation is actually the CV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the time of the last quantifiable data point.
Note the standard deviation is actually the CV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Measured Concentration (Tmax)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Time from dosing to the maximum concentration of the analyte in plasma.
Note the standard deviation is actually the CV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Rate Constant in Plasma (λz)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Terminal elimination rate constant in plasma.
Note the standard deviation is actually the CV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life in Plasma (T1/2)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Terminal half-life of the analyte in plasma.
Note the standard deviation is actually the CV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time in the Body After Oral Administration (MRTpo)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Mean residence time of the analyte in the body after oral administration.
Note the standard deviation is actually the CV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance After Extravascular Administration (CL/F)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Apparent clearance of the analyte in the plasma after extravascular administration.
Note the standard deviation is actually the CV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution During the Terminal Phase (Vz/F)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Apparent volume of distribution during the terminal phase (λz).
Note the standard deviation is actually the CV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator.</measure>
    <time_frame>Drug administration up to 7 days after last drug administration, up to 8 days</time_frame>
    <description>Clinically relevant abnormalities for physical examination, vital signs, ECG, blood chemistry and assessment of tolerability by the investigator. New abnormal findings or worsening of baseline conditions were reported as adverse events.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 treatments will be investigated in randomized order</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 treatments will be investigated in randomized order</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 treatments will be investigated in randomized order</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C: BI 10773 / metformin tablet</intervention_name>
    <description>BI 10773 / metformin fixed dose combination tablet after a high fat, high caloric meal</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B: BI 10773 tablet and metformin tablet</intervention_name>
    <description>BI 10773 and metformin single tablets, administered together in fasted state</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A: BI 10773 / metformin tablet</intervention_name>
    <description>BI 10773 / metformin fixed dose combination tablet in fasted state</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy males and females according to the following criteria

          2. Body Mass Index 18.5 to 29.9 kg/m2 (incl.)

        Exclusion criteria:

          1. Any finding of the medical examination (including Blood Pressure, Pulse Rate and
             electrocardiogram) deviating from normal and of clinical relevance

          2. Any evidence of a clinically relevant concomitant disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1276.5.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biberach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2010</study_first_submitted>
  <study_first_submitted_qc>September 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2010</study_first_posted>
  <results_first_submitted>June 26, 2015</results_first_submitted>
  <results_first_submitted_qc>July 27, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 21, 2015</results_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>An open label, randomised, three-way crossover study. A washout period of at least 7 days was respected between drug administrations.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FDC Fasted / Individual Tablets Fasted / FDC Fed</title>
          <description>Patients received the three treatments in the following order:
FDC tablet, containing 12.5mg empagliflozin (BI 10773) and 1000mg metformin, under fasted conditions
12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions
FDC tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions</description>
        </group>
        <group group_id="P2">
          <title>FDC Fasted / FDC Fed / Individual Tablets Fasted</title>
          <description>Patients received the three treatments in the following order:
FDC tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions
FDC tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions
12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions</description>
        </group>
        <group group_id="P3">
          <title>Individual Tablets Fasted / FDC Fasted / FDC Fed</title>
          <description>Patients received the three treatments in the following order:
12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions
FDC tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions
FDC tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions</description>
        </group>
        <group group_id="P4">
          <title>Individual Tablets Fasted / FDC Fed / FDC Fasted</title>
          <description>Patients received the three treatments in the following order:
12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions
FDC tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions
FDC tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions</description>
        </group>
        <group group_id="P5">
          <title>FDC Fed / FDC Fasted / Individual Tablets Fasted</title>
          <description>Patients received the three treatments in the following order:
FDC tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions
FDC tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions
12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions</description>
        </group>
        <group group_id="P6">
          <title>FDC Fed / Individual Tablets Fasted / FDC Fasted</title>
          <description>Patients received the three treatments in the following order:
FDC tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions
12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions
FDC tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 1 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 2 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 2 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 3 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Overall</title>
          <description>An open label, randomised, three-way crossover study. The three treatments administered were
Fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions
12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions
Fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions
A washout period of at least 7 days was respected between drug administrations.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.8" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Empa: Area Under the Curve 0 to Infinity (AUC0-∞)</title>
        <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity.
Note the standard deviation is actually the coefficient of variation (CV).</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.</population>
        <group_list>
          <group group_id="O1">
            <title>FDC Fasted</title>
            <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Individual Tablets Fasted</title>
            <description>12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>FDC Fed</title>
            <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Empa: Area Under the Curve 0 to Infinity (AUC0-∞)</title>
          <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity.
Note the standard deviation is actually the coefficient of variation (CV).</description>
          <population>Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.</population>
          <units>nmol*h/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2920" spread="16.2"/>
                    <measurement group_id="O2" value="2860" spread="18.5"/>
                    <measurement group_id="O3" value="2710" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ratio calculated as FDC fasted divided by individual tablets fasted.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>100.59</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>7.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.75</ci_lower_limit>
            <ci_upper_limit>105.67</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the intra-individual geometric coefficient of variation (gCV).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ratio calculated as FDC fed divided by FDC fasted</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>94.94</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>8.0</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.85</ci_lower_limit>
            <ci_upper_limit>100.33</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Empa: Maximum Measured Concentration (Cmax)</title>
        <description>Maximum measured concentration of empagliflozin (empa) in plasma.
Note the standard deviation is actually the CV.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.</population>
        <group_list>
          <group group_id="O1">
            <title>FDC Fasted</title>
            <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Individual Tablets Fasted</title>
            <description>12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>FDC Fed</title>
            <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Empa: Maximum Measured Concentration (Cmax)</title>
          <description>Maximum measured concentration of empagliflozin (empa) in plasma.
Note the standard deviation is actually the CV.</description>
          <population>Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="404" spread="17.4"/>
                    <measurement group_id="O2" value="405" spread="15.8"/>
                    <measurement group_id="O3" value="259" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ratio calculated as FDC fasted divided by individual tablets fasted</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>99.31</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>12.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.76</ci_lower_limit>
            <ci_upper_limit>107.49</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ratio calculated as FDC fed divided by FDC fasted</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>64.30</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>20.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>55.97</ci_lower_limit>
            <ci_upper_limit>73.87</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Empa: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)</title>
        <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the time of the last quantifiable data point.
Note the standard deviation is actually the CV.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.</population>
        <group_list>
          <group group_id="O1">
            <title>FDC Fasted</title>
            <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Individual Tablets Fasted</title>
            <description>12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>FDC Fed</title>
            <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Empa: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)</title>
          <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the time of the last quantifiable data point.
Note the standard deviation is actually the CV.</description>
          <population>Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.</population>
          <units>nmol*h/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2860" spread="16.3"/>
                    <measurement group_id="O2" value="2800" spread="18.6"/>
                    <measurement group_id="O3" value="2640" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ratio calculated as FDC fasted divided by individual tablets fasted</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>100.94</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>7.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.03</ci_lower_limit>
            <ci_upper_limit>106.11</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ratio calculated as FDC fed divided by FDC fasted</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>94.39</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>8.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.22</ci_lower_limit>
            <ci_upper_limit>99.87</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metformin: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)</title>
        <description>Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the time of the last quantifiable data point.
Note the standard deviation is actually the CV.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.</population>
        <group_list>
          <group group_id="O1">
            <title>FDC Fasted</title>
            <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Individual Tablets Fasted</title>
            <description>12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>FDC Fed</title>
            <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)</title>
          <description>Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the time of the last quantifiable data point.
Note the standard deviation is actually the CV.</description>
          <population>Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9900" spread="17.9"/>
                    <measurement group_id="O2" value="9720" spread="22.3"/>
                    <measurement group_id="O3" value="9550" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ratio calculated as FDC fasted divided by individual tablets fasted</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>103.13</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>11.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.59</ci_lower_limit>
            <ci_upper_limit>111.25</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ratio calculated as FDC fed divided by FDC fasted</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>96.96</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>15.5</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.23</ci_lower_limit>
            <ci_upper_limit>107.78</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Metformin: Area Under the Curve 0 to Infinity (AUC0-∞)</title>
        <description>Area under the concentration-time curve of metformin in plasma over the time interval from 0 extrapolated to infinity.
Note the standard deviation is actually the CV.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.</population>
        <group_list>
          <group group_id="O1">
            <title>FDC Fasted</title>
            <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Individual Tablets Fasted</title>
            <description>12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>FDC Fed</title>
            <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin: Area Under the Curve 0 to Infinity (AUC0-∞)</title>
          <description>Area under the concentration-time curve of metformin in plasma over the time interval from 0 extrapolated to infinity.
Note the standard deviation is actually the CV.</description>
          <population>Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10300" spread="16.9"/>
                    <measurement group_id="O2" value="10100" spread="21.2"/>
                    <measurement group_id="O3" value="10200" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ratio calculated as FDC fasted divided by individual tablets fasted</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>102.15</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>13.0</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.87</ci_lower_limit>
            <ci_upper_limit>111.15</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ratio calculated as FDC fed divided by FDC fasted</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>100.67</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>13.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.70</ci_lower_limit>
            <ci_upper_limit>110.51</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Metformin: Maximum Measured Concentration (Cmax)</title>
        <description>Maximum measured concentration of metformin in plasma.
Note the standard deviation is actually the CV.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.</population>
        <group_list>
          <group group_id="O1">
            <title>FDC Fasted</title>
            <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Individual Tablets Fasted</title>
            <description>12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>FDC Fed</title>
            <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin: Maximum Measured Concentration (Cmax)</title>
          <description>Maximum measured concentration of metformin in plasma.
Note the standard deviation is actually the CV.</description>
          <population>Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1550" spread="19.1"/>
                    <measurement group_id="O2" value="1530" spread="23.4"/>
                    <measurement group_id="O3" value="1180" spread="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ratio calculated as FDC fasted divided by individual tablets fasted</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>103.49</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>12.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.30</ci_lower_limit>
            <ci_upper_limit>112.39</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ratio calculated as FDC fed divided by FDC fasted</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>75.13</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>24.5</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>63.68</ci_lower_limit>
            <ci_upper_limit>88.64</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Measured Concentration (Tmax)</title>
        <description>Time from dosing to the maximum concentration of the analyte in plasma.
Note the standard deviation is actually the CV.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.</population>
        <group_list>
          <group group_id="O1">
            <title>FDC Fasted</title>
            <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Individual Tablets Fasted</title>
            <description>12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>FDC Fed</title>
            <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Measured Concentration (Tmax)</title>
          <description>Time from dosing to the maximum concentration of the analyte in plasma.
Note the standard deviation is actually the CV.</description>
          <population>Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax of empagliflozin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="34.2" lower_limit="0.67" upper_limit="2.50"/>
                    <measurement group_id="O2" value="1.75" spread="27.1" lower_limit="1.00" upper_limit="2.50"/>
                    <measurement group_id="O3" value="3.00" spread="54.6" lower_limit="1.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax of metformin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="20.9" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="2.50" spread="26.3" lower_limit="1.50" upper_limit="4.00"/>
                    <measurement group_id="O3" value="3.00" spread="49.8" lower_limit="1.50" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Rate Constant in Plasma (λz)</title>
        <description>Terminal elimination rate constant in plasma.
Note the standard deviation is actually the CV.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.</population>
        <group_list>
          <group group_id="O1">
            <title>FDC Fasted</title>
            <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Individual Tablets Fasted</title>
            <description>12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>FDC Fed</title>
            <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Rate Constant in Plasma (λz)</title>
          <description>Terminal elimination rate constant in plasma.
Note the standard deviation is actually the CV.</description>
          <population>Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.</population>
          <units>1/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>λz of empagliflozin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0559" spread="43.9"/>
                    <measurement group_id="O2" value="0.0601" spread="53.2"/>
                    <measurement group_id="O3" value="0.0498" spread="46.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>λz of metformin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0822" spread="73.3"/>
                    <measurement group_id="O2" value="0.0756" spread="82.7"/>
                    <measurement group_id="O3" value="0.0590" spread="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life in Plasma (T1/2)</title>
        <description>Terminal half-life of the analyte in plasma.
Note the standard deviation is actually the CV.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.</population>
        <group_list>
          <group group_id="O1">
            <title>FDC Fasted</title>
            <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Individual Tablets Fasted</title>
            <description>12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>FDC Fed</title>
            <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life in Plasma (T1/2)</title>
          <description>Terminal half-life of the analyte in plasma.
Note the standard deviation is actually the CV.</description>
          <population>Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T1/2 of empagliflozin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" spread="46.6"/>
                    <measurement group_id="O2" value="16.0" spread="61.3"/>
                    <measurement group_id="O3" value="16.7" spread="43.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1/2 of metformin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6" spread="94.6"/>
                    <measurement group_id="O2" value="17.8" spread="76.9"/>
                    <measurement group_id="O3" value="30.5" spread="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Residence Time in the Body After Oral Administration (MRTpo)</title>
        <description>Mean residence time of the analyte in the body after oral administration.
Note the standard deviation is actually the CV.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.</population>
        <group_list>
          <group group_id="O1">
            <title>FDC Fasted</title>
            <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Individual Tablets Fasted</title>
            <description>12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>FDC Fed</title>
            <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time in the Body After Oral Administration (MRTpo)</title>
          <description>Mean residence time of the analyte in the body after oral administration.
Note the standard deviation is actually the CV.</description>
          <population>Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MRTpo of empagliflozin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="17.6"/>
                    <measurement group_id="O2" value="10.9" spread="25.1"/>
                    <measurement group_id="O3" value="13.9" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRTpo of metformin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.53" spread="52.0"/>
                    <measurement group_id="O2" value="10.2" spread="52.1"/>
                    <measurement group_id="O3" value="19.4" spread="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance After Extravascular Administration (CL/F)</title>
        <description>Apparent clearance of the analyte in the plasma after extravascular administration.
Note the standard deviation is actually the CV.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.</population>
        <group_list>
          <group group_id="O1">
            <title>FDC Fasted</title>
            <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Individual Tablets Fasted</title>
            <description>12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>FDC Fed</title>
            <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance After Extravascular Administration (CL/F)</title>
          <description>Apparent clearance of the analyte in the plasma after extravascular administration.
Note the standard deviation is actually the CV.</description>
          <population>Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CL/F of empagliflozin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162" spread="15.0"/>
                    <measurement group_id="O2" value="166" spread="17.1"/>
                    <measurement group_id="O3" value="174" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CL/F of metformin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1670" spread="20.2"/>
                    <measurement group_id="O2" value="1730" spread="25.4"/>
                    <measurement group_id="O3" value="1670" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution During the Terminal Phase (Vz/F)</title>
        <description>Apparent volume of distribution during the terminal phase (λz).
Note the standard deviation is actually the CV.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.</population>
        <group_list>
          <group group_id="O1">
            <title>FDC Fasted</title>
            <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Individual Tablets Fasted</title>
            <description>12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>FDC Fed</title>
            <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution During the Terminal Phase (Vz/F)</title>
          <description>Apparent volume of distribution during the terminal phase (λz).
Note the standard deviation is actually the CV.</description>
          <population>Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vz/F of empagliflozin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210" spread="45.3"/>
                    <measurement group_id="O2" value="222" spread="58.0"/>
                    <measurement group_id="O3" value="250" spread="44.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vz/F of metformin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2410" spread="99.5"/>
                    <measurement group_id="O2" value="2650" spread="86.0"/>
                    <measurement group_id="O3" value="4670" spread="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator.</title>
        <description>Clinically relevant abnormalities for physical examination, vital signs, ECG, blood chemistry and assessment of tolerability by the investigator. New abnormal findings or worsening of baseline conditions were reported as adverse events.</description>
        <time_frame>Drug administration up to 7 days after last drug administration, up to 8 days</time_frame>
        <population>Treated set (TS) includes all subjects who took at least 1 dose of investigational medication and was used for safety analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>FDC Fasted</title>
            <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Individual Tablets Fasted</title>
            <description>12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>FDC Fed</title>
            <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator.</title>
          <description>Clinically relevant abnormalities for physical examination, vital signs, ECG, blood chemistry and assessment of tolerability by the investigator. New abnormal findings or worsening of baseline conditions were reported as adverse events.</description>
          <population>Treated set (TS) includes all subjects who took at least 1 dose of investigational medication and was used for safety analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Drug administration up to 7 days after last drug administration, up to 8 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FDC Fasted</title>
          <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions.</description>
        </group>
        <group group_id="E2">
          <title>Individual Tablets Fasted</title>
          <description>12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions.</description>
        </group>
        <group group_id="E3">
          <title>FDC Fed</title>
          <description>A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

